Related Experiment Videos
Hypertension after renal transplantation
M R First1, J F Neylan, L L Rocher
1Division of Nephrology and Hypertension, University of Cincinnati Medical Center, OH 45267-0585.
Journal of the American Society of Nephrology : JASN
|February 1, 1994
Summary
Post-transplant hypertension is common and increases cardiovascular risk. Calcium channel blockers are recommended for managing cyclosporine-induced hypertension in organ transplant recipients.
Area of Science:
- Nephrology
- Cardiology
- Transplantation Medicine
Background:
- Post-transplant hypertension is a frequent complication in organ transplant recipients, increasing risks for cardiovascular disease and graft dysfunction.
- Multiple mechanisms contribute to post-transplant hypertension, with chronic rejection being a primary cause before cyclosporine A.
- The introduction of cyclosporine A has significantly increased hypertension prevalence in solid organ transplant recipients.
Framework:
- Cyclosporine A elevates blood pressure by increasing renal vascular resistance through afferent arteriole vasoconstriction.
- Understanding the pathophysiology of cyclosporine-associated hypertension is crucial for effective management.
- Aggressive treatment of hypertension is vital in all transplant recipients to prevent allograft and cardiovascular damage.
Implementation:
- Calcium channel blockers are suggested as the initial therapeutic choice for patients with cyclosporine-associated hypertension.
- This approach targets the specific mechanism of cyclosporine-induced vasoconstriction.
- Early and effective intervention is key.
Implications:
- Effective management of post-transplant hypertension can mitigate serious complications.
- Optimizing cardiovascular health and graft function in transplant patients is a primary goal.
- Further research into tailored antihypertensive strategies may improve long-term outcomes.